ClinicalTrials.gg
RecruitingNCT07485075StenoFOODAppUpdated Mar 20, 2026

Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial

An interventional study of StenoFood App in Diabetes Type 2 and Kidney Disease, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Steno Diabetes Center Copenhagen · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 8 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.

Planned enrollment
7th of 24
104 · median 94
Started
2026
with 3 others
No phase
17 of 31
5 open now
Registered
28th of 31
by date

Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 with no phase, and was the 28th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, or all of them as a file.
02

Study summary

This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease (eGFR 30-59 ml/min).

Read the detailed description

The study investigates the effect of a newly developed digital education platform, the StenoFOOD app, which provides personalized dietary guidance for individuals with type 2 diabetes and reduced kidney function. Participants are followed for six months, during which changes in sodium and protein intake are assessed, together with blood pressure and several exploratory outcomes.

Participants are assigned to one of two groups. The intervention group is recruited from Steno Diabetes Center Copenhagen and receives the app-based educational program, which includes dietary guidance and self-monitoring tools. The control group is recruited from Nordsjællands Hospital and receives standard care in the diabetes outpatient clinic. The primary outcome is the change in sodium intake, estimated from 24-hour urinary sodium excretion. Secondary outcomes include changes in protein intake, while exploratory outcomes cover blood pressure, albuminuria, potassium and phosphate excretion, food literacy, digital health literacy, and patient-reported measures.

Eligibility requires a diagnosis of type 2 diabetes, age between 18 and 74 years, a BMI below 35, and moderately reduced kidney function. Participants must also have stable medical treatment for at least three months and be able to read and understand Danish. Exclusion criteria include other types of diabetes, active cancer, certain gastrointestinal conditions, a vegan diet, or the use of sodium chloride tablets. Access to the digital platform is required for those assigned to the intervention arm.

The study is conducted at Steno Diabetes Center Copenhagen in Herlev and at Nordsjællands Hospital in Hillerød. It is sponsored by Steno Diabetes Center Copenhagen with collaboration from Rigshospitalet and Nordsjællands Hospital. The study has been approved by the Regional Ethics Committee in the Capital Region of Denmark.A total of 104 participants are expected to be enrolled.

03

Conditions studied

  • Diabetes Type 2
  • Kidney Disease

Keywords

  • Type 2 Diabetes, Chronic Kidney Disease, Digital Health, Dietary Intervention, KDIGO Guidelines
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes (ICD-10 DE11.x)
  • Age 18-74 years
  • \< 35 kg/m²
  • 30-59 ml/min and UACR > 30 mg/g
  • Stable medication for ≥3 months
  • Ability to read and understand Danish

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes or other diabetes types
  • Current vegan diet
  • Active cancer
  • Short bowel syndrome or celiac disease
  • Use of sodium chloride tablets
  • No access to digital platform (intervention group only)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Other
    Standard care

    Standard care at diabetes outpatient clinic

    Device: StenoFood App

Interventions

  • DeviceStenoFood App

    Digital patient education program (app-based) with dietary guidance and self-monitoring tools

    Also known as: SBI-Steno_Food_Concept

06

What researchers measure

Primary outcomes

  1. Change in sodium excretion between measurements at baseline and 6 months follow-up

    Sodium intake (g/day) will be estimated by the average of 2 collections of 24-hour urinary sodium at both baseline and follow-up

    Time frame: 6 month

Secondary outcomes

  1. Change in protein intake (g/kg/day) between baseline and follow-up measurements

    Protein intake will be estimated from the average of 2 collections of 24 hour urinary urea nitrogen at both baseline and follow-up

    Time frame: 6 months

  2. Change in Blood pressure between baseline and follow-up

    average of the two last blood preassure measurements out of three

    Time frame: 6 months

  3. Change in albumin, potassium and phosphate excretion between baseline and follow-up

    biochemical analysis of albumin, potassium, phosphate excreted in 2\* 24 hour urine collections at baseline and follow-up

    Time frame: 6 month

  4. Change in dietary patterns between baseline and follow-up

    at both baseline and follow-up participants will fill in a three day food record as well as screeners for salt and protein intake

    Time frame: 6 months

Other outcomes

  1. Changes between baseline and follow-up in blood lipids

    At both baseline and follow-up participants and controls will have blood samples taken for biochemical analyses of blood lipids

    Time frame: 6 months

  2. Change in selfreported health, motivation, self efficcacy, food and healthy literacy baseline and follow-up

    at both baseline and follow-up participants will answer questionnaires on food literacy, health literacy, selfperceived health, motivation, selfefficacy and health literacy

    Time frame: 6 months

  3. Salt intake measured by spot-urine dipstick measurements

    Feasibility study of dipstick measurements for self-monitoring of saltintake based on two morning and one evening measurements by the Quantab chloride dipsticks

    Time frame: every month participants are invited to take three spoturine sample over 24 hrs and measure them with the Quantab chloride dipsticks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Alhashimi L, Cordwin DJ, Dandu C, Hummel SL, Dorsch MP. Patient self-assessment of urine dipsticks to estimate sodium intake in patients with hypertension. Clin Nutr ESPEN. 2022 Oct;51:295-300. doi: 10.1016/j.clnesp.2022.08.011. Epub 2022 Aug 12. PubMed 36184219 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2027, 21 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 21 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartEst.
Mar 20, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485075
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Mar 20, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion